The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
50
1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
Department of Haematology L, Herlev Hospital, Herlev Ringvej 75
Herlev, Denmark
To evaluate a possible protective effect of bismuth on the mucous membranes during chemotherapy and radiotherapy
Time frame: daily during treatment
To identify the effect of bismuth on the regulation of metallothionein in tumour tissue and healthy tissue, respectively
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.